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Calcium-Channel Blockers Do Not Alter the Clinical
Efficacy of Clopidogrel After Myocardial Infarction
A Nationwide Cohort Study
Jonas B. Olesen, MB, Gunnar H. Gislason, MD, PHD, Mette G. Charlot, MD,
Emil L. Fosbøl, MD, PHD, Charlotte Andersson, MB, Peter Weeke, MD, Ole Ahlehoff, MD,
Christian Selmer, MD, Christian Torp-Pedersen, MD, DMSC, Peter R. Hansen, MD, PHD, DMSC
Hellerup, Denmark
Objectives The purpose of this study was to determine the risk of adverse cardiovascular events associated with concomi-
tant use of clopidogrel and calcium-channel blockers (CCBs) in patients with myocardial infarction (MI).
Background CCBs inhibit a variety of cytochrome P-450 enzymes, some of which contribute to clopidogrel metabolic activa-
tion. This interaction may diminish the efficacy of clopidogrel.
Methods All patients surviving 30 days after a first-time MI in the period 2000 to 2006 in Denmark were identified by
individual-level linkage of nationwide administrative registers. The cohort was divided into patients treated with
and without clopidogrel and followed for 1 year after discharge. The risk of a composite of cardiovascular death,
MI, or stroke and the risk of the individual components of the composite end point and all-cause death associ-
ated with CCBs were analyzed with multivariable Cox proportional hazard models and in univariate propensity
score-matched models.
Results A total of 56,800 patients were included, of whom 24,923 were treated with clopidogrel and 13,380 with CCBs.
In the Cox analyses, the risk of the composite end point associated with CCBs was increased in both patients
treated and not treated with clopidogrel, with a hazard ratio of 1.15 (95% confidence interval [CI]: 1.07 to 1.24)
and 1.05 (95% CI: 1.01 to 1.11), respectively. The increased risk was independent of clopidogrel use; the hazard
rate ratio was 1.08 (95% CI: 0.99 to 1.18). Analyses of all additional adverse end points and propensity score–
matched models provided similar results.
Conclusions The clinical efficacy of clopidogrel in patients with a recent MI is not modified by concomitant CCB treatment.
This potential drug interaction is unlikely to have clinical significance. (J Am Coll Cardiol 2011;57:409–17)
© 2011 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.08.640c
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Rlopidogrel is a thienopyridine that by inhibiting the
latelet P2Y12 adenosine diphosphate receptor reduces the
isk of new atherothrombotic events in patients after myo-
ardial infarction (MI) and after percutaneous coronary
ntervention (1,2). Clopidogrel is a prodrug that is metab-
lized to its active thiol metabolite by a variety of hepatic
ytochrome P-450 (CYP) enzymes, including the 3A4 and
C19 isoforms (3–6). Calcium-channel blockers (CCBs),
hich are widely used for the treatment of hypertension and
ngina pectoris, are metabolized by the same CYP3A4
nzymes as clopidogrel (7–9). Therefore, it has been pro-
osed that CCBs can interfere with the metabolism of
rom the Department of Cardiology, Copenhagen University Hospital Gentofte,
ellerup, Denmark. The authors have reported that they have no relationships to
isclose.n
Manuscript received March 28, 2010; revised manuscript received August 12, 2010,
ccepted August 18, 2010.lopidogrel to its active form and thereby reduce the clinical
fficacy of clopidogrel. Recent studies have demonstrated a
iminished effect of clopidogrel by reduced ex vivo platelet
nhibition in patients treated concomitantly with CCBs
10–12). However, although patients with MI are often
reated with both a CCB and clopidogrel, the clinical
mportance of this hypothetical drug interaction has never
een examined on a population level. We therefore per-
ormed a nationwide study including all patients discharged
fter a first-time MI in Denmark. By using nationwide
egistries of hospitalizations and drug dispensing from
harmacies, we analyzed the effect of CCBs on clinical end
oints in patients treated and not treated with clopidogrel.
ethods
egistry data sources. In Denmark, a unique and perma-
ent civil registration number for every citizen enables
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mation from nationwide admin-
istrative registries. Since 1978, all
admissions to Danish hospitals
are registered in the Danish Na-
tional Patient Registry with 1
primary and, if appropriate, 1
secondary discharge diagnoses
according to the International
Classification of Diseases (ICD)
(13). Since 1995, all prescrip-
tions dispensed from Danish
harmacies are accurately registered in the Danish Registry
f Medicinal Product Statistics (prescription registry) ac-
ording to the international Anatomical Therapeutic
hemical (ATC) classification system (14). The civil reg-
stration system holds information on vital statistics for all
itizens and the National Causes of Death Registry holds
nformation on primary and contributing causes of death.
tudy population and outcomes. From the National Pa-
ient Registry, we identified all patients hospitalized with a
rst-time MI in the period 2000 to 2006 in Denmark (Fig. 1).
reatment with clopidogrel (ATC: B01AC04) was defined
y claimed prescriptions within 30 days of discharge. The
se of clopidogrel has been found to be stable over time in
his cohort with 1-year continuation of use in 89% of the
atients after 2004 (15). To avoid immortal time bias (i.e.,
void predicting on the future), we only included patients
urviving 30 days after discharge. Exposure to CCBs (ATC:
08) was also defined according to prescription claims, but
ecause the continuation of CCB treatment has never been
Abbreviations
and Acronyms
ATC  Anatomical
Therapeutic Chemical
CCB  calcium-channel
blocker
CYP  cytochrome P-450
ICD  International
Classification of Diseases
MI  myocardial infarction
Figure 1 Selection of Study Population
CCB  calcium-channel blocker.alidated in this population, exposure to CCBs was defined
s a time-dependent covariate in the follow-up period.
CBs were divided into their main pharmacological sub-
lasses (i.e., verapamil [ATC: C08DA01], diltiazem [ATC:
08DB01], and dihydropyridines [ATC: C08CA01]) and
nto high- and low-dose administration with the following
utoff values for high daily doses: verapamil 240 mg,
iltiazem 240 mg, amlodipine 5 mg, felodipine 5 mg,
sradipine 2.5 mg, lacidipine 2 mg, lercanidipine 10
g, nifedipine 40 mg, nimodipine 2 mg, and nitren-
ipine10 mg. Patients emigrating during the study period
ere censored at the time of emigration. The primary study
utcome was a combined end point of cardiovascular death
ICD-10: I00 to I99), rehospitalization for nonfatal MI
ICD-10: I21 to I22), or nonfatal stroke (ICD-10: I63 to
66). Secondary outcomes were the individual components
f the combined end point and all-cause death. The MI and
troke diagnoses were previously validated in the National
atient Registry (16,17). The population was followed for 1
ear after discharge.
omorbidity, socioeconomic status, and concomitant
edication. Comorbidity was defined by diagnoses at dis-
harge after the index MI as specified in the Ontario acute
I mortality prediction rule (18). The comorbidity index
as further enhanced by adding diagnoses from the year
efore the index event, as done by Rasmussen et al. (19).
e used treatment with loop diuretics (ATC: C03C) and
lucose-lowering drugs (ATC: A10) up to 90 days after
ischarge as proxies for heart failure and diabetes mellitus,
espectively, as done previously (20). Socioeconomic status
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January 25, 2011:409–17 Calcium-Channel Blockers and Clopidogrelas defined by the individual average annual gross income
uring the 5-year period before inclusion, and patients were
ivided in quintiles according to their income. From the
rescription registry, we also obtained information on
aseline Characteristics of Patients With First-Time Myocardial InfTable 1 Baseline Characteristics of Patients With First-Time M
Treatment With Clopidogr
(n  24,923)
Without CCB
(n  19,201)
With CCB
(n  5,722)
Overall age, yrs 64.6 12.7 66.5 12.2
Men 13,494 (70.3) 3,630 (63.4)
Age, yrs 62.8 12.2 64.8 11.9
Women 5,707 (29.7) 2,092 (36.6)
Age, yrs 69.1 12.7 69.3 12.2
Year of inclusion
2000–2002 4,074 (21.2) 1,446 (25.3)
2003–2004 7,463 (38.9) 2,135 (37.3)
2005–2006 7,664 (39.9) 2,141 (37.4)
Income group
0 (lowest income quintile) 1,764 (9.2) 724 (12.7)
1 2,423 (12.6) 914 (16.0)
2 3,913 (20.4) 1,235 (21.6)
3 4,438 (23.1) 1,256 (22.0)
4 (highest income quintile) 6,663 (34.7) 1,593 (27.8)
PCI 13,357 (69.6) 3,329 (58.2)
Comorbidity
Shock 131 (0.7) 28 (0.5)
DM with complications 746 (3.9) 325 (5.7)
Peptic ulcer 168 (0.9) 68 (1.2)
Pulmonary edema 128 (0.7) 33 (0.6)
Peripheral vascular disease 193 (1.0) 100 (1.8)
Cerebrovascular disease 584 (3.0) 232 (4.1)
Cancer 63 (0.3) 16 (0.3)
Cardiac dysrhythmias 1,382 (7.2) 455 (8.0)
Acute renal failure 77 (0.4) 41 (0.7)
Chronic renal failure 113 (0.6) 115 (2.0)
Concomitant medication
Loop diuretic 5,268 (27.4) 1,775 (31.0)
Spironolactone 1,557 (8.1) 405 (7.1)
Aspirin 13,960 (72.7) 3,699 (64.7)
Vitamin K antagonist 992 (5.2) 275 (4.8)
Statin 16,905 (88.0) 4,973 (86.9)
Beta-blocker 17,147 (89.3) 4,441 (77.6)
ACE inhibitor 9,889 (51.5) 3,066 (53.6)
Glucose-lowering drug 2,034 (10.6) 844 (14.8)
Verapamil 572 (10.0)
Diltiazem 526 (9.2)
Dihydropyridines 4,624 (80.8)
Amlodipine 3,990 (69.7)
Felodipine 312 (5.5)
Isradipine 19 (0.3)
Lacidipine 13 (0.2)
Lercanidipine 46 (0.8)
Nifedipine 237 (4.1)
Nimodipine 0 (0.0)
Nitrendipine 7 (0.1)alues are mean  SD or n (%).
ACE  angiotensin-converting enzyme; CCB  calcium-channel blocker; DM  diabetes mellitus; PCI laimed prescriptions up to 90 days after discharge for the
ther concomitant medications listed in Table 1.
tatistical analyses. For the baseline characteristics, com-
arisons of categorical and continuous covariates were
n Surviving 30 Days From Dischargerdial Infarction Surviving 30 Days From Discharge
No Treatment With Clopidogrel
(n  31,877)
p Value for
Difference
Without CCB
(n  24,219)
With CCB
(n  7,658)
p Value for
Difference
0.001 71.2 13.4 71.0 12.5 0.22
0.001 14,339 (59.2) 4,300 (56.2) 0.001
0.001 68.2 13.2 68.5 12.3 0.30
0.001 9,880 (40.8) 3,358 (43.9) 0.001
0.46 75.5 12.5 74.2 11.9 0.001
0.001 0.001
14,758 (60.9) 4,885 (63.8)
5,838 (24.1) 1,732 (22.6)
3,623 (15.0) 1,041 (13.6)
0.001 0.001
4,013 (16.6) 1,465 (19.1)
5,571 (23.0) 1,782 (23.3)
5,203 (21.5) 1,584 (20.7)
4,873 (20.1) 1,510 (19.7)
4,559 (18.8) 1,317 (17.2)
0.001 2,276 (9.4) 631 (8.2) 0.002
0.11 364 (1.5) 88 (1.2) 0.02
0.001 1,341 (5.5) 505 (6.6) 0.001
0.03 548 (2.3) 162 (2.1) 0.45
0.46 361 (1.5) 92 (1.2) 0.06
0.001 469 (1.9) 215 (2.8) 0.001
0.001 1,568 (6.5) 467 (6.1) 0.24
0.57 104 (0.4) 25 (0.3) 0.22
0.06 3,301 (13.6) 1,115 (14.6) 0.04
0.002 285 (1.2) 127 (1.7) 0.001
0.001 374 (1.5) 215 (2.8) 0.001
0.001 11,796 (48.7) 3,586 (46.8) 0.004
0.01 3,217 (13.3) 803 (10.5) 0.001
0.001 11,643 (48.1) 3,615 (47.2) 0.18
0.28 2,251 (9.3) 774 (10.1) 0.03
0.02 11,418 (47.1) 4,120 (53.8) 0.001
0.001 17,336 (71.6) 4,735 (61.8) 0.001
0.006 10,349 (42.7) 3,228 (42.2) 0.37
0.001 3,051 (12.6) 1,141 (14.9) 0.001
1,308 (17.1)
1,062 (13.9)
5,288 (69.0)
4,522 (59.1)
344 (4.5)
35 (0.5)
26 (0.3)
35 (0.5)
311 (4.1)
1 (0.0)
14 (0.2)arctioyoca
elpercutaneous coronary intervention.
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Calcium-Channel Blockers and Clopidogrel January 25, 2011:409–17erformed by the chi-square test and Student t test, respec-
ively. For all analyses, a 2-sided p value 0.05 was
onsidered statistically significant. To estimate the risk
ssociated with CCBs with or without concomitant treat-
ent with clopidogrel, we used 2 different methods. First,
ox proportional hazard models were constructed for the
ntire population. The models were adjusted for age, sex,
ercutaneous coronary intervention, income, concomitant
edication, and comorbidity. Exposure to CCBs was in-
luded in the models as a time-dependent covariate (i.e.,
atients were only considered at risk when they were taking
CBs). For sensitivity analyses, we performed separate
nalyses for the main pharmacological subclasses of CCBs,
igh- and low-dose CCB exposure, and selected patient
ubgroups. Additionally, we performed propensity score–
atched analyses. A propensity score for the likelihood of
eceiving CCBs within the first year from discharge was
uantified by a multivariable logistic regression analysis
onditional on the baseline covariates. Using the Greedy
atching macro (21), each CCB-exposed patient was
atched by propensity score to 1 nonexposed control
ubject from the study population. The risk associated with
CB use in the propensity score-matched groups was
ubsequently estimated in univariate Cox proportional haz-
rd models. In all Cox models, the model assumptions (i.e.,
roportional hazards, linearity of continuous covariates, and
ack of interactions) were tested systematically and found to
e valid unless otherwise indicated. All analyses were
erformed with SAS version 9.1 (SAS Institute Inc., Cary,
orth Carolina).
thics. No ethical approval is required for retrospective
egistry studies in Denmark. The study was approved by
he Danish Data Protection Agency (no. 2003-54-1269).
esults
he Danish population age 10 years or older on January 1,
997, comprised 4,614,807 individuals. We identified
1,987 patients hospitalized with MI during this 7-year
tudy period, of which 56,800 patients had a first-time MI
nd met the inclusion criterion of 30 days survival from
ischarge (Fig. 1). Clopidogrel treatment was initiated in
isk Associated With CCB TreatmentTable 2 Risk Associated With CCB Treatment
Treatment With Clopidogrel
(n  24,923)
Without CCB
(n  19,201)
HR
With CCB
(n  5,722)
HR (95% CI) p Value
MI, stroke, or CV death 1.00 1.15 (1.07–1.24) 0.001
MI 1.00 1.35 (1.20–1.52) 0.001
Stroke 1.00 1.14 (0.95–1.36) 0.15
CV death 1.00 1.05 (0.89–1.24) 0.56
All-cause death 1.00 0.97 (0.83–1.13) 0.67
p value for interaction between CCBs and clopidogrel.
CCB  calcium-channel blocker; CI  confidence interval; CV  cardiovascular; HR  hazard ratio; HR4,923 patients (43.9%) within 30 days after discharge, and
he use of CCBs during the 1-year follow-up period was
dentified in 5,722 patients (23.0%) receiving clopidogrel
nd 7,658 patients (24.0%) not receiving clopidogrel. Of
atients treated with a CCB during follow-up, 47.4%,
7.2%, 66.5%, and 70.1% were receiving CCB treatment at
ays 30, 90, 180, and 360 after discharge, respectively. The
aseline characteristics of the study population are shown in
able 1. Men composed 63.0% of the population, and their
ean age was 68.5  13.3 years. Overall, patients were
ore likely to begin clopidogrel treatment at the end of the
tudy period, and patients treated with clopidogrel were
ounger, more often men, had less comorbidity, and had
ore often undergone percutaneous coronary intervention.
f patients treated with CCBs in the 1-year follow-up
eriod, 74.1% were treated with a dihydropyridine (pre-
ominantly amlodipine). Patients treated with a CCB more
ften had diabetes mellitus and previous hospital admissions
or renal failure (Table 1).
ime-dependent Cox proportional hazard analyses. As
hown in Table 2, the Cox proportional hazard analyses
emonstrated an increased risk of the composite end point
f cardiovascular death, rehospitalization for MI, or stroke
ssociated with CCBs in patients treated with clopidogrel
hazard ratio: 1.15; 95% confidence interval [CI]: 1.01 to
.10) and in those not treated with clopidogrel (hazard
atio: 1.05; 95% CI: 1.01 to 1.11). The hazard rate ratio for
nteraction between CCBs and clopidogrel was 1.08 (95%
I: 0.99 to 1.18; p  0.08), indicating no significant effect
odification of CCBs and clopidogrel treatment on the
rimary study outcome. The results from the analyses of the
econdary outcomes (i.e., cardiovascular death, rehospital-
zation for MI, stroke, and all-cause death) gave similar
esults (Table 2). For the composite end point, we found no
nteraction between any of the CCB subclasses and clopi-
ogrel (Fig. 2). Additionally, we found no interaction of the
isk of the composite end point between clopidogrel and
ither high- or low-dose CCB treatment (p value for
nteraction was 0.60 and 0.64, respectively). The analyses in
elected patient subgroups yielded similar results (Fig. 3).
No Treatment With Clopidogrel
(n  31,877)
Likelihood for Difference With
CCB Treatment
out CCB
24,219)
HR
With CCB
(n  7,658)
HR (95% CI) p Value HRR (95% CI) p Value*
.00 1.05 (1.01–1.10) 0.03 1.08 (0.99–1.18) 0.08
.00 1.27 (1.16–1.40) 0.001 1.05 (0.90–1.22) 0.51
.00 1.20 (1.07–1.34) 0.002 0.98 (0.80–1.20) 0.83
.00 1.00 (0.92–1.09) 0.96 1.11 (0.93–1.34) 0.25
.00 0.97 (0.90–1.04) 0.36 1.05 (0.89–1.25) 0.54With
(n 
1
1
1
1
1R  hazard rate ratio; MI  myocardial infarction.
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January 25, 2011:409–17 Calcium-Channel Blockers and Clopidogrelropensity score–matched time-dependent Cox proportional-
azard analyses. Using logistic regression models condi-
ional on baseline covariates (Table 1), we estimated the
ropensity for receiving CBBs for each patient. Logistical
egression was performed in the total study population and
n 2 separate models including patients treated and not
reated with clopidogrel. In the overall regression model,
statistics were 0.61 both with and without clopidogrel (i.e.,
lopidogrel as an explanatory covariate did not improve the
iscriminatory power of the model). In the models of
atients treated and not treated with clopidogrel, the c sta-
istics were 0.64 and 0.60, respectively, indicating acceptable
iscriminatory power of the models. Additional results of
he logistic regression used for the propensity score-
atching are given in the Online Appendix. In patients
Figure 2 Risk of Cardiovascular Death, Myocardial Infarction, o
Results from adjusted time-dependent Cox proportional hazard analyses. Error bar
treated and not treated with clopidogrel were 0.08, 0.65, 0.37, and 0.08 for all C
blocker; HR  hazard ratio.
Figure 3 Risk of Cardiovascular Death, Myocardial Infarction, o
Results from adjusted time-dependent Cox proportional-hazard analyses. Error bar
p value for the difference between corresponding paired subpopulations (i.e., subj
women, and so on) was not significant. PCI  percutaneous coronary intervention;eceiving clopidogrel, the median propensity score for ini-
iating CCB treatment was 23.5% (interquartile range: 18.6
o 31.5) for both patients treated and those not treated with
CBs, respectively. In patients not receiving clopidogrel,
he median propensity score was 25.0% (interquartile range:
0.4 to 30.3) for both the CCB and non-CCB treated,
espectively. By individual propensity scores, 5,692 patients
eceiving both clopidogrel and CCB treatment were
atched 1:1 with patients treated with clopidogrel and no
CB. In the same manner, 7,658 patients treated with
CBs and no clopidogrel were matched with patients not
reated with either CCBs or clopidogrel. Baseline charac-
eristics of the propensity score–matched populations and
values for differences between groups are displayed in
able 3. Results of the univariate Cox analyses of the
oke According to CCB Subgroups and Clopidogrel Treatment
trate 95% confidence intervals. p values for the difference between patients
erapamil, diltiazem, and dihydropyridines, respectively. CCB  calcium-channel
oke Associated With CCBs in Selected Subpopulations
rate 95% confidence intervals. In both groups (clopidogrel or no clopidogrel), the
0 years of age and older vs. those younger than 70 years of age, men vs.
abbreviations as in Figure 2.r Str
s illus
CBs, vr Str
s illust
ects 7
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Calcium-Channel Blockers and Clopidogrel January 25, 2011:409–17ropensity score–matched groups were concordant with the
ndings of the nonmatched primary analyses (Table 4).
djusting the propensity score–matched Cox analyses for
ovariates with minor differences between the CCB and
on-CBB treated (i.e., year of inclusion, vitamin K antag-
nist, and angiotensin-converting enzyme inhibitors) did
ot alter the results.
iscussion
n this nationwide cohort of patients discharged after a
rst-time MI, treatment with a CBB was not associated with
ignificant changes in clopidogrel efficacy across a range of
dverse cardiovascular end points and all-cause mortality in
aseline Characteristics for the Propensity Score–Matched PopulaTable 3 Baseline Characteristics for the Propensity Score–Mat
Treatment With Clopidogr
(n  11,384)
Without CCB
(n  5,692)
With CCB
(n  5,692)
Overall age, yrs 66.2 12.7 66.4 12.2
Men 3,594 (63.1) 3,622 (63.6)
Age, yrs 64.3 12.2 64.8 11.9
Women 2,098 (36.9) 2,070 (36.4)
Age, yrs 70.0 12.7 69.3 12.2
Year of inclusion
2000–2002 1,354 (23.8) 1,433 (25.1)
2003–2004 2,203 (38.7) 2,122 (37.3)
2005–2006 2,135 (37.5) 2,137 (37.5)
Income group
0 (lowest income quintile) 682 (12.0) 719 (12.6)
1 893 (15.7) 903 (15.9)
2 1,264 (22.2) 1,228 (21.6)
3 1,307 (23.0) 1,251 (22.0)
4 (highest income quintile) 1,546 (27.2) 1,591 (28.0)
PCI 3,282 (57.7) 3,326 (58.4)
Comorbidity
Shock 32 (0.6) 28 (0.5)
DM with complications 325 (5.7) 321 (5.6)
Peptic ulcer 63 (1.1) 68 (1.2)
Pulmonary edema 26 (0.5) 33 (0.6)
Peripheral vascular disease 93 (1.6) 93 (1.6)
Cerebrovascular disease 208 (3.7) 230 (4.0)
Cancer 20 (0.4) 16 (0.3)
Cardiac dysrhythmias 406 (7.1) 449 (7.9)
Acute renal failure 36 (0.6) 39 (0.7)
Chronic renal failure 81 (1.4) 103 (1.8)
Concomitant medication
Loop diuretic 1,732 (30.4) 1,758 (30.9)
Spironolactone 397 (7.0) 404 (7.1)
Aspirin 3,744 (65.8) 3,695 (64.9)
Vitamin K antagonist 261 (4.6) 275 (4.8)
Statin 4,980 (87.5) 4,948 (86.9)
Beta-blocker 4,435 (77.9) 4,435 (77.9)
ACE inhibitor 3,175 (55.8) 3,050 (53.6)
Glucose-lowering drug 846 (14.9) 835 (14.7)
alues are mean  SD or n (%). “With CCB” refers to patients treated with a CCB at some point in
Abbreviations as in Table 1.ither multivariable or propensity score–matched time- rependent Cox proportional-hazard analyses. The results were
onsistent for all the main CCB pharmacological subclasses, in
oth high- and low-dose CCB treatment and in different
atient subpopulations. We found that the use of CCBs was
ssociated with increased cardiovascular risk after MI indepen-
ent of concomitant treatment with clopidogrel. However,
mlodipine was the most commonly used CCB, and results
ith the other CCBs were conducted with less power. The
esults suggest the absence of a clinically significant interaction
etween CCBs and clopidogrel and that the increased risk
ssociated with CCBs may be explained by unmeasured
onfounders. Along this line, we found that CCBs were more
requently administered to patients with diabetes mellitus or
ith a First-Time Myocardial InfarctionPopulation With a First-Time Myocardial Infarction
No Treatment With Clopidogrel
(n  15,316)
p Value for
Difference
Without CCB
(n  7,658)
With CCB
(n  7,658)
p Value for
Difference
0.36 71.1 13.0 71.0 12.5 0.44
0.59 4,273 (55.8) 4,300 (56.2) 0.66
0.05 68.4 12.9 68.5 12.3 0.81
0.59 3,385 (44.2) 3,358 (43.9) 0.66
0.41 74.6 12.3 74.2 11.9 0.18
0.15 0.02
5,010 (65.4) 4,885 (63.8)
1,712 (22.4) 1,732 (22.6)
936 (12.2) 1,041 (13.6)
0.73 0.46
1,489 (19.4) 1,465 (19.1)
1,849 (24.1) 1,782 (23.3)
1,501 (19.6) 1,584 (20.7)
1,505 (19.7) 1,510 (19.7)
1,314 (17.2) 1,317 (17.2)
0.40 597 (7.8) 631 (8.2) 0.31
0.60 81 (1.1) 88 (1.2) 0.59
0.87 482 (6.3) 505 (6.6) 0.45
0.66 141 (1.8) 162 (2.1) 0.22
0.36 88 (1.2) 92 (1.2) 0.76
1.00 219 (2.9) 215 (2.8) 0.85
0.28 460 (6.0) 467 (6.1) 0.81
0.50 23 (0.3) 25 (0.3) 0.77
0.13 1,069 (14.0) 1,115 (14.6) 0.29
0.73 114 (1.5) 127 (1.7) 0.40
0.10 216 (2.8) 215 (2.8) 0.96
0.60 3,527 (46.1) 3,586 (46.8) 0.34
0.80 762 (10.0) 803 (10.5) 0.27
0.33 3,590 (46.9) 3,615 (47.2) 0.69
0.54 676 (8.8) 774 (10.1) 0.007
0.37 4,072 (53.2) 4,120 (53.8) 0.44
1.00 4,791 (62.6) 4,735 (61.8) 0.35
0.02 3,254 (42.5) 3,228 (42.2) 0.67
0.77 1,128 (14.7) 1,141 (14.9) 0.77
year follow-up period.tion Wched
elenal failure.
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January 25, 2011:409–17 Calcium-Channel Blockers and ClopidogrelNo interaction was found between CCBs and the year of
atient inclusion and the risk of the composite end point.
evertheless, in patients included after 2004, a nonsignifi-
ant trend for a higher risk with CCBs in patients treated
ith clopidogrel was observed (Fig. 3). Interpretation of this
esult is difficult because after 2004, patients treated or not
reated with clopidogrel probably displayed more confound-
ng differences in baseline covariates than patients included
n the earlier study period because after 2004, guideline-
ased recommendations for clopidogrel in patients with MI
ad been more firmly adopted. Moreover, the trend for
ncreased risk with CCBs in patients receiving clopidogrel
fter 2004 was not reproduced in the propensity score–
atched analysis.
Hepatic metabolism is necessary to generate the active
lopidogrel metabolite through a 2-step oxidative process
riven by the CYP system. The first step that leads to
-oxo-clopidogrel is catalyzed by 3 enzymes (CYP1A2,
YP2B6, and CYP2C19), and the second step that gener-
tes the pharmacologically active metabolite involves 4
nzymes (CYP3A4, CYP2B6, CYP2C9, and CYP2C19)
22). CYP2C19 is active in both oxidative steps, but a recent
tudy found that a polymorphism of CYP2C19 (CYP2C19*2)
ad only little influence on the platelet-inhibiting effect of
lopidogrel (23). All CBBs are metabolized by CYP3A4 (7–9),
nd the importance of CYP3A4 for clopidogrel bioactivation
as been amply demonstrated by significant variations in
lopidogrel responsiveness as measured by ex vivo platelet
ctivation in subjects with CYP3A4 polymorphisms (3,4).
urthermore, other CYP enzymes that contribute to clopi-
ogrel bioactivation participate in CBB degradation (e.g.,
YP1A2 and CYP2C9 for verapamil) (24). In potential
greement with the shared metabolic mechanisms between
lopidogrel and CCBs, recent observational studies found
educed clopidogrel responsiveness as determined by increased
x vivo residual platelet activation in patients with MI who
ere treated with CCBs, and in 2 of these studies, the reduced
ffect was associated with adverse short-term cardiovascular
utcomes (10–12). On the other hand, the absence of acute
ffects of intravenous verapamil on the platelet inhibition
isk Associated With CCB TreatmentTable 4 Risk Associated With CCB Treatment
Treatment With Clopidogrel
Without CCB
(n  5,692)
With CCB
(n  5,692)
W
(n
HR HR (95% CI) p Value
MI, stroke, or CV death 1.00 1.17 (1.08–1.28) 0.001
MI 1.00 1.30 (1.14–1.49) 0.001
Stroke 1.00 1.31 (1.08–1.59) 0.007
CV death 1.00 1.14 (0.94–1.37) 0.18
All-cause death 1.00 1.09 (0.91–1.29) 0.35
esults from propensity score–matched, time-dependent Cox proportional hazard models. *p valu
Abbreviations as in Table 2.chieved by a 600-mg loading dose of clopidogrel has been deported, suggesting that a CCB-clopidogrel interaction may
ot be clinically relevant (25).
Previously, concerns of inhibited clopidogrel bioactiva-
ion by drug interactions with CYP enzymes have been
ntertained with statins and proton pump inhibitors (26–28).
any statins, including simvastatin and atorvastatin, are
etabolized by CYP3A4, but early reports of reduced
ntiplatelet effects of clopidogrel as measured by various ex
ivo assays during cotreatment with these statins were
ubsequently countered by numerous studies showing that
uch interaction, if present, was not clinically significant
29 –32). Proton pump inhibitors are metabolized by
YP2C19, and reports of reduced platelet responsiveness to
lopidogrel during cotreatment with proton pump inhibi-
ors were first supported by observational studies in selected
opulations indicating an association with adverse cardio-
ascular events (33,34). Recently, these initial findings were
uestioned by post hoc analyses of large randomized clinical
rials in which proton pump inhibitors were associated with
ncreased risk of adverse cardiovascular events irrespective of
he use of clopidogrel (35). Our study supports a similar
onclusion for the potential CCB-clopidogrel interaction in
atients after MI (i.e., treatment with CCBs is associated
ith an adverse prognosis independent of cotreatment with
lopidogrel), indicating that a specific pharmacological in-
eraction between these agents is not clinically important
nd that the increased risk associated with CCBs may be
xplained by confounding. In this context, it should also be
mphasized that although reduced clopidogrel responsive-
ess as determined by ex vivo platelet function tests appears
o be associated with increased risk of adverse cardiovascular
vents, the power of these tests to predict such events at
resent seems to be limited (36–38).
tudy strengths and limitations. The main strength of
his study was the nationwide complete data sources. No-
ably, we had accurate and complete information on all
rescriptions dispensed nationwide in Denmark. Further-
ore, the study population represented an unselected cohort
f post-MI patients in a contemporary clinical setting. The
ain study limitation was inherent to its observational
No Treatment With Clopidogrel
Likelihood for Difference With
CCB Treatment
CCB
658)
With CCB
(n  7,658)
HR (95% CI) p Value HRR (95% CI) p Value*
1.14 (1.09–1.21) 0.001 1.00 (0.90–1.10) 0.93
1.21 (1.09–1.34) 0.001 1.03 (0.87–1.22) 0.71
1.24 (1.09–1.40) 0.001 1.06 (0.84–1.33) 0.63
1.25 (1.14–1.38) 0.001 0.93 (0.75–1.14) 0.46
1.21 (1.11–1.32) 0.001 0.91 (0.75–1.10) 0.34
teraction between CCBs and clopidogrel.ithout
 7,
HR
1.00
1.00
1.00
1.00
1.00esign. We had no information on the precise indication for
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Calcium-Channel Blockers and Clopidogrel January 25, 2011:409–17CB treatment (i.e., leaving room for effects of unmeasured
onfounders and confounding by indication). For example,
esidual confounding may have contributed to the increased
isk observed with CCBs, and patients treated or not treated
ith clopidogrel might have differed with respect to unmea-
ured confounders (e.g., perceived bleeding risk), which may
ave influenced the results. Amlodipine was the most used
CB, and therefore, results with dihydropyridines had
ore power than the results with the 2 other CCB sub-
lasses. Furthermore, it was not possible to check whether
he patients actually used the dispensed medication, and we
ere not able to account for important prognostic factors
elated to cardiovascular disease such as smoking, physical
ctivity, left ventricular ejection fraction, and body mass
ndex. Moreover, clopidogrel resistance is linked to CYP
enotype polymorphisms that display ethnic variations, and
eneralization of the results from our study population
omposed of almost exclusively white patients to other racial
nd ethnic groups should be made with caution (39,40).
onclusions
n patients with MI, we found no evidence of a clinically
ignificant effect modification between CCBs and clopi-
ogrel regarding the risk of new adverse cardiovascular
vents. The results of this study do not support safety
oncerns with concomitant treatment with CCBs and
lopidogrel.
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